Abstract:Nutritional risk index (NRI) is an index based on ideal body weight that aims to present body weight and serum albumin levels. It has been utilized to discriminate patients at risk of postoperative complications and predict the postoperative outcome of major surgeries. However, this index remains limited for breast cancer patients treated with neoadjuvant chemotherapy (NACT). The research explores the clinical and prognostic significance of NRI in breast cancer patients. This study included 785 breast cancer patients (477 cases received NACT and 308 cases did not) were enrolled in this retrospective study. The optimal NRI cutoff value was evaluated by receiver operating characteristic (ROC) curve, then reclassified as low NRI group (<112) and high NRI group (≥112). The results demonstrated that NRI independently predicted survival on disease-free survival (DFS) and overall survival (OS) by univariate and multivariate Cox regression survival analyses [P = 0.019, hazard ratio (HR): 1.521, 95% CI: 1.071–2.161 and P = 0.004, HR: 1.415, 95% CI: 1.119–1.789; and P = 0.026, HR:1.500, 95% CI: 1.051–2.143 and P < 0.001, HR: 1.547, 95% CI: 1.221–1.959]. According to the optimal cutoff value of NRI, the high NRI value patients had longer mean DFS and OS time in contrast to those with low NRI value patients (63.47 vs. 40.50 months; 71.50 vs. 56.39 months). Furthermore, the results demonstrated that the high NRI score patients had significantly longer mean DFS and OS time than those with low NRI score patients in early-stage breast cancer (χ2 = 9.0510, P = 0.0026 and χ2 = 9.2140, P = 0.0024) and advanced breast cancer (χ2 = 6.2500, P = 0.0124 and χ2 = 5.8880, P = 0.0152). The mean DFS and OS values in patients with high NRI scores were significantly longer in contrast to those with low NRI scores in different molecular subtypes. The common toxicities after NACT were hematologic and gastrointestinal reactions, and the NRI had no statistically significant effects on toxicities, except in nausea (χ2 = 9.2413, P = 0.0024), mouth ulcers (χ2 = 4.8133, P = 0.0282), anemia (χ2 = 8.5441, P = 0.0140), and leukopenia (χ2 = 11.0951, P = 0.0039). NRI serves as a minimally invasive, easily accessible and convenient prognostic tool for evaluating breast cancer prognoses and treatment efficacy, and may help doctors in terms of selecting measures of greater efficiency or appropriateness to better treat breast cancer.

A combined nutritional risk index and carcinoembryonic antigen score predicts the outcome in radically resected colorectal cancer

Combined Detection of Preoperative Neutrophil-To-Lymphocyte Ratio and Cea As an Independent Prognostic Factor in Nonmetastatic Patients Undergoing Colorectal Cancer Resection is Superior to Nlr or Cea Alone

Combination of Carcinoembryonic Antigen with the American Joint Committee on Cancer TNM Staging System in Rectal Cancer: a Real-World and Large Population-Based Study

Prognostic and Survival Analysis of 837 Chinese Colorectal Cancer Patients.

A Large-Scale Study Integrating Nutritional Indicators and Clinicopathological Parameters to Evaluate Prognosis, Follow-Up, and Postoperative Chemotherapy Decisions in Rectal Cancer Patients

Pretreatment NRS-2002 scores combined with hematologic inflammation markers are independent prognostic factors in patients with resectable thoracic esophageal squamous cell carcinoma.

Comprehensive Malnutritional Index for Predicting Clinical Outcomes in Locally Advanced Rectal Cancer Receiving Neoadjuvant Chemoradiotherapy

A Novel Prognostic Model Incorporating Carcinoembryonic Antigen in 3-Week or Longer Postoperative Period for Stage III Colon Cancer: A Multicenter Retrospective Study

A novel prognosis marker based on combined preoperative carcinoembryonic antigen and systemic inflammatory response for resectable gastric cancer

Postoperative Carcinoembryonic Antigen (CEA) Levels Predict Outcomes after Resection of Colorectal Cancer in Patients with Normal Preoperative CEA Levels.

Grading carcinoembryonic antigen levels can enhance the effectiveness of prognostic stratification in patients with colorectal cancer: a single-centre retrospective study

Nutritional Risk Index as a Prognostic Factor Predicts the Clinical Outcomes in Patients With Stage III Gastric Cancer

Nutritional Risk Index Predicts Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy

The Novel CFP Scoring System is a Reliable Marker in Predicting Response and Prognosis in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

Predictive Value of Nutritional Risk Screening 2002 and Prognostic Nutritional Index for Esophageal Cancer Patients Undergoing Definitive Radiochemotherapy

A novel inflammation-based prognostic score for patients with esophageal squamous cell carcinoma: the c-reactive protein/prognostic nutritional index ratio

Predictive Value of Combined Preoperative Carcinoembryonic Antigen Level and Ki-67 Index in Patients With Gastric Neuroendocrine Carcinoma After Radical Surgery

IDDF2021-ABS-0036 Prognostic Value of the CEA, RDW-CV, RDW-SD Combined with CIP2A in the Serum of Patients with Colorectal Cancer

Combined neat model for the prognosis of postoperative stage III-N2 non-small cell lung cancer

Neutrophil-Lymphocyte Ratio and Circulating Tumor Cells Counts Predict Prognosis in Gastrointestinal Cancer Patients

A Novel Prognostic Score, Based on Preoperative Nutritional Status, Predicts Outcomes of Patients after Curative Resection for Gastric Cancer